Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 8/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2609365 | 0.88 | KMO (0.45) | HSD17B14CNR2CNR1TRPV3KMO | |
| SCHEMBL18014721 | 0.86 | CNR2 (0.51) | HSD17B14CNR2CNR1TRPV3KMO | |
| SCHEMBL2609333 | 0.86 | KMO (0.45) | TRPV3KMOABL1 | |
| SCHEMBL2609345 | 0.86 | TRPV3 (0.43) | HSD17B14TRPV3KMOCTSAIRAK4 | |
| SCHEMBL2609346 | 0.83 | TRPV3 (0.45) | HSD17B14TRPV3CTSAIRAK4 | |
| SCHEMBL2609328 | 0.81 | CNR2 (0.44) | CNR2CNR1TRPV3KMO | |
| SCHEMBL2609330 | 0.80 | HSD11B1 (0.40) | CNR2CNR1TRPV3 | |
| SCHEMBL16533199 | 0.80 | TRPV3 (0.46) | HSD17B14CNR2CNR1TRPV3KMO | |
| SCHEMBL2609353 | 0.80 | KMO (0.46) | HSD17B14KMOCTSAIRAK4 | |
| SCHEMBL2609335 | 0.78 | NOTUM (0.48) | TRPV3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052495-B1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2015049616-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | HSD17B14 1232/4885CNR2 464/4885CNR1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.